Latest stories on TCRX
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral
TScan Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.05M misses by $0.83M
Seeking Alpha34 · bearishearnings
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Business Insider56 · neutralgeneral
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Business Insider63 · neutralproduct/pr
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
TipRanks67 · bullishproduct/pr
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
Yahoo Top56 · neutralearnings
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
TipRanks42 · neutralgeneral